Page 660 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

644 PART 8 ■ Fundamentals of Hematological Analysis

CASE STUDIES (continued)
CASE STUDIES (continued)

Her WBC histogram appears below. T e platelet count was 23

decreased. All erythrocytic parameters were within normal

ranges; however, the values tended to be in the low ends o

the ranges.

21

25
19
fL

29
17
■ Questions 15 27 1
1. Do the histogram or other leukocyte results demon- 13 9 11 7

strate any abnormalities?

2. What type o disorder, i any, is suggested by the WBC

results and histogram?

3. What urther laboratory testing should be considered? 0.2 0.3 0.4

12
Platelet count (x 10 /L)
Case Study 30.5

■ Critical Thinking Group Discussion Questions
■ Laboratory Data 1. Did the patient have an initial abnormality?
A 12-year-old black boy had a total leukocyte count o

55.0 × 10 /L. His histogram appears below. 2. Did the patient develop any abnormalities ollowing
9
His platelet count was low, as were his erythrocyte treatment?

parameters. Additionally, his platelet histogram was

abnormal. 3. Did the patient’s values return to normal?

Case Study 30.7

■ History and Physical

M.W., a 50-year-old male clinical laboratory scientist, saw
his primary care provider or an examination prior to a

6-month international volunteer assignment. He elt well
and had no symptoms o any abnormalities.

A urinalysis and CBC were ordered.

■ Critical Thinking Group Discussion Questions ■ Laboratory Data

1. Do the histogram or other leukocyte results demon- Urinalysis: All results within re erence ranges.

strate any abnormalities?
■ Hematology Laboratory

2. What type o disorder, i any, is suggested by the WBC Measurement Patient Data Reference Range*

results and histogram?

RBC 5.03 × 10 /µL 4.00–6.20
6
3. What urther laboratory testing should be considered? Hgb 15.2 g/dL 11.0–18.8

Hct 45% 35.0–55.0
Case Study 30.6
WBC 5.1 × 10 /µL 6.0–11.0
3
■ Laboratory Data PLT 175 × 10 /µL 150.0–400.0
3
A 28-year-old white woman underwent a chemothera- MCV 89 fL 80.0–100.0

peutic regimen or the treatment o leukemia. Her ini-

tial platelet count and MPV as well as successive platelet MCH 30 pg 26.0–34.0

counts and MPVs, beginning on the 7th day a er the ter- MCHC 34 g/dL 31.0–35.0

mination o treatment, were assayed every other day and RDW 18% 10.0–20.0

charted by the laboratory. MPV 9.1 fL 6.0–10.0

fL, femtoliters; pg, pictogram.

* Published for Beckman Coulter A T .
C TM